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Abstract
Periodontitis is an inflammatory disease of the supporting structures of the teeth caused by, among other pathogens,
Prevotella intermedia. Many strains of P. intermedia are resistant to killing by the human complement system, which is
present at up to 70% of serum concentration in gingival crevicular fluid. Incubation of human serum with recombinant
cysteine protease of P. intermedia (interpain A) resulted in a drastic decrease in bactericidal activity of the serum.
Furthermore, a clinical strain 59 expressing interpain A was more serum-resistant than another clinical strain 57, which did
not express interpain A, as determined by Western blotting. Moreover, in the presence of the cysteine protease inhibitor
E64, the killing of strain 59 by human serum was enhanced. Importantly, we found that the majority of P. intermedia strains
isolated from chronic and aggressive periodontitis carry and express the interpain A gene. The protective effect of interpain
A against serum bactericidal activity was found to be attributable to its ability to inhibit all three complement pathways
through the efficient degradation of the a-chain of C3—the major complement factor common to all three pathways. P.
intermedia has been known to co-aggregate with P. gingivalis, which produce gingipains to efficiently degrade complement
factors. Here, interpain A was found to have a synergistic effect with gingipains on complement degradation. In addition,
interpain A was able to activate the C1 complex in serum, causing deposition of C1q on inert and bacterial surfaces, which
may be important at initial stages of infection when local inflammatory reaction may be beneficial for a pathogen. Taken
together, the newly characterized interpain A proteinase appears to be an important virulence factor of P. intermedia.
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Introduction
Periodontitis is an inflammatory condition with an infective
etiology that leads to loss of tooth support. Prevotella intermedia is a
major bacterial periodontal pathogen in humans together with
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans [1]. P.
intermedia is often recovered from subgingival plaque in patients
suffering from acute necrotising gingivitis, pregnancy gingivitis and
chronic periodontitis [2]. Recently, P. intermedia was reported to be
found in 14% of adult population in Finland and there was
association between the carriage of this species and the number of
teeth with deepened periodontal pockets [3]. P. intermedia was also
frequently isolated from root canal infections [4]. Periodontitis is
one of the most common diseases affecting humans and is
primarily the result of colonization of the subgingival surfaces of
teeth by bacteria. The complex interaction between these bacteria
harboring many virulence factors and the host’s immune response
results in localized chronic inflammation and subsequent destruc-
tion of the supporting structures of the tooth. Proteinases are
crucial virulence factors produced by many periodontal pathogens,
which can cause the degradation of host proteins for essential
nutrients but they can also protect the bacteria from the host’s
defenses such as the complement system [5,6].
Complement is a major arm of the innate immune defense system
and its main function is to recognize and destroy microorganisms
[7]. The three pathways of human complement ensure that virtually
any non-host surface is recognized as hostile. The classical pathway
is usually mediated by binding of the C1 complex (composed of
recognition molecule C1q and two proteinases C1s and C1r) to
invading pathogens either directly or via immunoglobulins. The
lectin pathway is able to recognize, via mannose-binding lectin
(MBL), polysaccharide molecules normally present only on
microbial surfaces. Finally, complement can also be activated
through the alternative pathway, which is not so much an activation
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pathway but as a failure to appropriately regulate the constant low-
level spontaneous activation of C3 (constantly initiated due to
inherent instability of this protein). All three pathways lead to
opsonisation of the pathogen with C3b (activated form of
complement factor C3), which enhances phagocytosis by phago-
cytes. Furthermore, anaphylatoxins C5a and C3a are released as
byproducts to attract phagocytes to the site of infection. Finally, the
end result of the complement cascade is formation of the membrane
attack complex and bacterial cell lysis. Host cells protect themselves
from bystander damage following complement activation through
the expression of membrane-bound or recruitment of soluble
endogenous complement inhibitors.
Complement deficiencies are very rare but it has been observed
that partial C4 gene deficiencies are more frequent in patients with
severe chronic periodontitis [8]. A patient with aggressive
periodontitis and severe edema, localized to the free gingival
tissues was reported to be deficient in C1-inhibitor [9].
Furthermore, the highest salivary levels of C3 were measured in
periodontally healthy subjects while low levels were often found in
edentulous and chronic periodontitis patients [10].
It has been demonstrated that heat inactivation of NHS (i.e.
inactivation of complement) significantly reduced opsonic activity
for P. intermedia in vitro [11] suggesting that complement is
important for host defense against this pathogen. Previous studies
have shown that P. intermedia was opsonized by the alternative
pathway in the absence of the classical pathway, probably in
response to the endotoxin [12], however, kinetic studies revealed
that opsonisation proceeded at significantly faster rates when the
classical pathway was intact [11]. Interestingly, the alternative
pathway contributed to the killing of serum sensitive strains while
the classical pathway was primarily responsible for killing of strains
with intermediate sensitivity [13]. Therefore, it appears that
complement is able to recognize P. intermedia via several sensory
molecules. However, it appears that P. intermedia is able to override
to some extent the complement defenses and to establish chronic
infections in the oral cavity.
Every successful human pathogen must develop means to
circumvent complement. Many bacteria are able to capture
human complement inhibitors such as C4b-binding protein and
factor H thereby inhibiting complement and avoiding opsonisation
and lysis [14–16]. Herpes viruses, on the other hand, produce their
own homologues of complement inhibitors [17]. Furthermore,
many bacteria use proteinases to incapacitate components of the
complement system. For example, most strains of P. gingivalis are
resistant to bacteriolytic activity of human serum [13,18] and the
gingipain proteinases have been implicated as the major factor
providing protection against complement in serum [5,19–22]. For
a number of Prevotella subspecies and strains, including P. intermedia,
the level of proteolytic activity for clinical strains was significantly
higher than that recorded for commensal strains isolated from
healthy mouths [23]. This, we hypothesize, may provide P.
intermedia with serum protection.
We have identified three cysteine proteinases in the genome of
P. intermedia that appeared to be homologues of SpeB protein of
Streptococcus pyogenes [24]. Recently, the first of these genes coding
for interpain A (InpA; locus PIN0048) was studied in more detail
and its 3D structure was determined [25]. Based on similarity of
primary and tertiary structures to known proteinases, InpA is now
classified into clan CA, family C10 and registered in the peptidase
database MEROPS ([26]; http://merops.sanger.ac.uk). InpA is a
secreted protein composed of 868 amino acid residues including a
44-residue signal peptide, a pro-domain (Ala1-Asn111), a catalytic
domain (Val112-Pro359) and a 465-residue C-terminal extension
arranged in domains with putative regulatory and secretory
functions. However, the specific target(s) and function of InpA
have yet to be characterized. In the present study, we have
examined in detail the effect of InpA on the human complement
system and found that this proteinase targets mainly the C3
component, thereby inhibiting all three complement pathways
simultaneously.
Results
inpA gene is present in the majority of the clinical isolates
of P. intermedia
In order to estimate what fraction of P. intermedia strains found in
periodontitis carry the inpA gene, detection by PCR was used on
subgingival plaque samples obtained from 24 and 58 patients with
chronic and aggressive periodontitis, respectively. We have
validated specificity of the PCR assay by investigating 25 samples
that were negative for P. intermedia but rich in other periodontal
pathogens. No positive signal was obtained in any of the tested
Prevotella-negative samples showing that the assay is specific for
Prevotella inpA gene (data not shown). P. intermedia was detected in
33% and 57% of plaque samples from chronic and aggressive
periodontitis, respectively (Table 1). The majority of P. intermedia-
positive samples also yielded positive results regarding the inpA
gene implying that InpA fulfils some important physiological
function. Similarly, we found that the majority of cultivated P.
intermedia strains from various sources also express InpA at the
protein level as shown by Western blotting analysis of culture
supernatants (Figure 1A). The upper band recognized by the
specific antibody corresponds to an unprocessed form of InpA
while the lower bands are products of autocatalytic processing
[25]. Western blotting of lysates of bacterial cells did not yield a
signal implying that InpA is mainly secreted by the bacteria and
does not associate in large amounts with cell wall in the strains
tested (data not shown).
Furthermore, we have detected InpA protein in gingival
crevicular fluid samples collected from four chronic periodontitis
patients characterized with regard to pocket depth and bleeding-
on-probing. The samples were analyzed for the P. intermedia load
Author Summary
Prevotella intermedia is one of the bacterial pathogens that
has been implicated in causing periodontitis—an endemic
inflammatory disease of the supporting structures of the
teeth. The complement system is an important part of host
innate immunity and is able to directly kill invading bacteria.
To become successful pathogens, many strains of P.
intermedia developed mechanisms making them very
resistant to killing by complement. We found that a cysteine
protease, interpain A, that is produced by many clinical
strains of P. intermedia was able to destroy the bacterial
killing activity of human serum. A strain of P. intermedia that
produces interpain A was found to be more resistant to
complement than the one lacking interpain A, and the
resistance of the interpain A–producing strain could be
diminished by a specific inhibitor of cysteine proteases. We
attributed the protective effect of interpain A to its ability to
inhibit the complement system through the efficient
degradation of C3—a major complement protein that is
common to all three pathways of complement activation.
Understanding the mechanism governing pathogen resis-
tance to complement may help us to design novel
therapeutic strategies to prevent or treat an important
bacterial disease.
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Table 1. Prevalence of Prevotella intermedia and the presence of interpain A in subgingival plaque samples.
Group (Numbers) Prevalence High Load ($106) inpA Gene Present
Healthy controls 0 0
Aggressive periodontitis (24) 8 (33%) 3 (13%) 6 of 8 (75%)
Chronic periodontitis (58) 33 (57%) 22 (38%) 25 of 31 (81%)
doi:10.1371/journal.ppat.1000316.t001
Figure 1. Interpain A destroys bactericidal activity of NHS. (A) Western blotting analysis of InpA expression. Five-day old broth cultures of
nine P. intermedia strains were adjusted to OD600 of 2, and the culture supernatants were separated by SDS-PAGE under reducing conditions and
proteins transferred onto PVDF membranes. InpA was visualized with polyclonal antibodies. One lane shows purified InpA. (B) Western blotting
analysis of gingival crevicular fluid (20 mL/lane) from patients with chronic periodontitis. Load of P. intermedia was determined with qPCR (,100
bacteria/sample ‘‘2’’, 100–1,000 bacteria/sample ‘‘+’’, 10,000–50 000 bacteria/sample ‘‘++’’, .50,000 bacteria/sample ‘‘+++’’). The leftmost lane
contains 1 mg of a purified inactive recombinant mutant, InpAC154A. (C) E. coli DH5a were incubated with 2% NHS pretreated with increasing
concentrations of InpA and InpAC154A, and the surviving bacteria were enumerated after overnight culture on LB agar plates. As a control, heat-
inactivated NHS (DNHS) was used, and the survival of bacteria in this condition was set to 100%. (D) P. intermedia and E. coli were incubated with 20%
NHS and 40% NHS for 1.5 h in anaerobic conditions, respectively, with and without supplementation with 1 mM E64 protease inhibitor, and the
surviving bacteria were enumerated after culture onto TSB and LB plates, respectively. In (C) and (D) an average of three independent experiments is
presented with bars indicating standard deviation (SD). Statistical significance of observed differences was estimated using Student’s t-test; n.s. not
significant, *p,0.05.
doi:10.1371/journal.ppat.1000316.g001
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using qPCR and subjected to Western blotting analysis. We
detected InpA in various forms in samples obtained from patients
with significant load of P. intermedia but not from those negative for
this pathogen (Figure 1B). The 90 kDa form is the unprocessed full
length protein, the 76 kDa and the 40 kDa proteins are processed
on the N-terminus and the C-terminus, respectively, while the
28 kDa form is the mature, fully-processed protein. These
molecular weights are calculated based on amino acid composi-
tion. The 40 kDa form runs in fact as 45 kDa protein (28 kDa
form as 32 kDa protein) upon separation on 12% SDS-PAGE gel.
Interpain A destroys the bactericidal activity of human
serum
In order to quantitatively assess the effect of purified InpA on the
bactericidal activity of human serum, we used an E. coli DH5a model
system whereby cells were incubated with normal human serum
(NHS) pretreated with various concentrations of InpA or its inactive
mutant (InpAC154A) and surviving cells enumerated by colony
counting. InpA was found to be able to destroy the bactericidal
activity of human serum in a dose-dependent manner and rescued E.
coli that are otherwise very sensitive to killing by NHS (Figure 1C).
Moreover, P. intermedia strains have been known to vary significantly
in their ability to resist killing by NHS [13], hence, various strains
were investigated to see if there was a relationship between the serum
resistance of a given strain and its InpA expression level. By Western
blotting, P. intermedia strain 59 producing a large amount of InpA was
found to have a 100% survival rate in 20% NHS while only 78% of
the strain 57 with non-detectable InpA production survived
(Figure 1A and 1D). Furthermore, addition of a cysteine proteinase
inhibitor E64 to NHS decreased the ability of P. intermedia strain 59 to
survive while it did not affect the killing of strain 57 or E. coli
(Figure 1D). Taken together, the results obtained with both purified
InpA and P. intermedia strains showed that InpA compromised the
bactericidal activity of human serum.
Interpain A destroys complement system in human
serum
In order to understand in detail how InpA destroys the
bactericidal activity of NHS, i.e. complement, the enzyme was
incubated at various concentrations with human serum and
hemolytic assays were used to assess activity of the classical and
alternative pathways of complement in the pre-treated sera. InpA
was found to be an efficient inhibitor of both pathways, whereas
the inactive mutant InpAC154A did not show any inhibition
(Figure 2A and 2B). InpA was able to inhibit the classical pathway
by 80% when present at high nanomolar concentrations (0.5 mM)
while the alternative pathway was inhibited by 80% at 1.5 mM
concentration. It should be noted, however, that 10% serum was
used for the alternative pathway hemolytic assay versus 1.25% for
the classical pathway. These concentrations were chosen on a basis
of the initial titration and represent conditions in which each assay
was most sensitive. The alternative pathway is known to require
high concentrations of serum in order to function properly in
contrast to the classical pathway that is rapidly activated even at
fractions of percent of NHS. Taken together, it appears that InpA
is approximately equally able to destroy activity of both the
classical and alternative pathways.
Interpain A interferes with all three pathways by
degrading mainly C3
Each complement pathway is composed of several factors
activated in a consecutive manner. In order to assess which
complement factor(s) were affected by InpA, a microtiter plate-
based assay in which complement activation was initiated by
various ligands depending on the pathway analyzed was used and
the deposition of successive complement factors was then detected
with specific antibodies. In the case of the classical pathway,
complement activation was initiated by immunoglobulin deposi-
tion. We found that depositions of C1 and C4 from 2% serum
were not affected by InpA (Figure 3A and 3B). However, C3 was
found to be sensitive to InpA and deposition of C3b from NHS
was abolished at 2 mM InpA (Figure 3C). The inactive
InpAC154A mutant had no effect on activation and deposition
of C3b at any concentration tested. Accordingly, deposition of C9
that appears in the cascade after C3 was inhibited at similar
concentrations as C3 indicating that the inhibitory effect on
deposition of C9 was due to degradation of C3 (Figure 3D).
For assessment of the lectin pathway, we used plates bound with
mannan carbohydrate. In this case, InpA did not affect the
binding of MBL, which is the initiator of the pathway (Figure 4A)
and weakly inhibited deposition of C4b (Figure 4B). However,
similar to the classical pathway, InpA strongly inhibited the
deposition of C3b and C9 while the InpAC154A mutant had no
effect (Figure 4C and 4D).
Figure 2. Interpain A destroys hemolytic activity of human
serum. Sheep erythrocytes sensitized with antibodies (classical
pathway, (A)) or rabbit erythrocytes (alternative pathway, (B)) were
incubated with 1.25% or 10% NHS, respectively. Serum was supple-
mented with various concentrations of InpA and InpAC154A. After 1 h
incubation, the degree of lysis was estimated by measurement of
released hemoglobin (absorbance at 405 nm). Lysis obtained in the
absence of interpain was set as 1. An average of three independent
experiments is presented with bars indicating SD.
doi:10.1371/journal.ppat.1000316.g002
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Figure 3. Interpain A inhibits the classical pathway. InpA and
InpAC154A were incubated with 2% NHS (for C1q, C4b, C3b assays) and
10% NHS (for C9 assay) for 15 min and inactivated with an excess of E64
(20 mM) to prevent degradation of IgGs. Human IgGs were immobilized
on microtiter plates and allowed to activate NHS pre-incubated with
various concentrations of InpA and InpAC154A. After 20 min (C3b, C4b)
and 45 min (C1q, C9) of incubation, the plates were washed, and
deposited C1q (A), C4b (B), C3b (C), and C9 (D) were detected with
specific polyclonal antibodies. Absorbance obtained in the absence of
InpA was set as 1.0 unit. An average of three independent experiments
is presented with bars indicating SD. Data points without error bars
have minimal SD, which are not displayed by the graphing software
(GraphPad Prism 4).
doi:10.1371/journal.ppat.1000316.g003
Figure 4. Interpain A inhibits the lectin pathway. Mannan was
immobilized on microtiter plates and allowed to activate 4% NHS (for
MBL, C4b, C3b assays) and 10% NHS (for C9 assay) that was pre-
incubated for 15 min with various concentrations of InpA and
InpAC154A. After 20 min (C3b, C4b) and 45 min (C9, MBL) of
incubation, the plates were washed, and deposited MBL (A), C4b (B),
C3b (C), and C9 (D) were detected with specific polyclonal antibodies.
Absorbance obtained in the absence of interpain was set as 1. An
average of three independent experiments is presented with bars
indicating SD.
doi:10.1371/journal.ppat.1000316.g004
Interpain A and Complement
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The alternative pathway was activated by immobilized zymosan
and InpA was found to be able to inhibit deposition of C3b and
C9 with a similar efficiency as previously found for the other two
pathways (Figure 5A and 5B). Taken together, all three pathways
were sensitive to InpA and its main target appeared to be C3,
which is the key protein for all pathways of the complement
system.
NHS contains several proteinase inhibitors that could poten-
tially inhibit the activity of InpA. However, we found that the
InpA activity measured with fluorogenic substrate was not affected
by NHS when NHS was present at concentrations up to 30%
(Figure 5C).
Interpain A attacks preferentially a-chains of C3 and C4
In order to assess the sites cleaved by InpA, in complement
factors, purified C3 and structurally related C4 were incubated
with InpA at various molar ratios. The proteins were then
separated by SDS-PAGE and visualized using silver staining
(Figure 6A and 6B). C3 is composed of covalently linked a- and b-
chains while C4 contains a-, b- and c-chains. For both proteins,
InpA first attacks the a-chain while the b-chain is relatively
resistant (Figure 6A–6D); which is similar to what we have
previously observed for gingipains [5]. The InpAC154A mutant
did not cause any degradation of C3 or C4 (Figure 6A and 6B).
Interestingly, similar concentrations of InpA were required for the
degradation of purified C3 and C4, whereas in the presence of
NHS, InpA preferentially inactivates C3 (Figures 3 and 4).
To determine sites of proteolysis by InpA, C3 and C4 were
treated with InpA and degradation products were separated by
SDS-PAGE electrophoresis. The proteins were transferred to
PVDF membrane, visualized with Coomassie (Figure 6E) and
selected bands were subjected to N-terminal sequencing. Interest-
ingly, cleavage of the C3 polypeptide chain at the site resulting in
the N-terminal sequence SNLDEDIIA generated the exact
sequence of an anaphylatoxin fragment C3a. Similarly, the
cleavage of C4 producing the N-terminal sequence ALEILQEE
generated the exact sequence of C4a. Sequence 2 (SPMYSII)
corresponds to the N-terminus of the C3 b-chain.
Kinetic parameters of C3 and C4 degradation by
interpain A
When degradation of C3 and C4 was assessed at a set
concentration of InpA for increasing incubation times, C4 was
degraded at a faster rate than C3 (Figure 7A). To determine the
kinetic parameters of degradation of C3b by InpA, surface
plasmon resonance was employed. When the inactive InpAC154A
proteinase was injected over immobilized C3b, no change in signal
was detected (data not shown). However, upon injection of InpA,
there was a rapid decrease in the signal measured in resonance
units (RU) corresponding to degradation of C3b. The initial rates
of proteolysis at each concentration of InpA were obtained from
the initial slopes in the sensorgrams (Figure 7B). In this system,
1000 RU corresponds to a mass shift of 1 ng/mm2. The analysis
demonstrated that 3 mM InpA degrades C3b at an initial rate of
7 pg/s (Figure 7B inset). The kinetic parameters of C3 and C4
degradation by InpA were also determined by fitting initial rates of
degradation of a-chains of C3 and C4 into Michaelis-Menten
equation. A constant amount of InpA was incubated with
increasing concentrations of C3 and C4 and the initial rate of
proteolysis at various substrate concentrations was estimated from
the decrease of intensity of scanned bands corresponding to a-
chains of C3 and C4 as resolved by SDS-PAGE. Using this
approach, Km and kcat for C4 degradation was determined to be
4.3+/20.8 mM and 0.026+/20.005 s21, respectively (Figure 7D).
Unfortunately, a reasonably accurate measurement of the kinetic
constants for C3 was not possible since there was no visible
saturation of the initial rate of C3 degradation up to 2 mg/mL
(10 mM) of substrate, hence, the Km could only be estimated as
greater than 20 mM (Figure 7C).
Figure 5. Interpain A inhibits the alternative pathway. Zymosan
was immobilized on microtiter plates and allowed to activate 6% NHS
(for C3b assay) and 10% NHS (for C9 assay) that was pre-incubated for
15 min with various concentrations of InpA and InpAC154A. After
20 min (C3b) and 45 min (C9) of incubation, the plates were washed,
and deposited C3b (A) and C9 (B) were detected with specific
polyclonal antibodies. Absorbance obtained in the absence of interpain
was set as 1. (C) InpA was incubated with increasing concentrations of
NHS, and the activity of InpA was determined using a synthetic
substrate. The cysteine protease inhibitor E64 was used as a control. An
average of three independent experiments is presented with bars
indicating SD.
doi:10.1371/journal.ppat.1000316.g005
Interpain A and Complement
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Interpain A causes activation and deposition of C1 in the
absence of any activator
We have observed previously that gingipains did not degrade
C1 but instead were able to cause C1 deposition on surfaces that
would not normally activate C1 [5]. In order to assess if this was
also the case for InpA, human serum was incubated with InpA in
the absence of any immobilized C1 activator and we observed that
it did cause deposition of C1q on the empty microtiter plates
blocked with BSA (Figure 8A). In the absence of InpA or in the
presence of its inactive mutant, the deposition of C1q from serum
was negligible as expected.
In addition, InpA was also found to be able to cause deposition
of C1q on bacterial surfaces. To this end, Prevotella nigrescens was
incubated with NHS containing InpA at different concentrations
Figure 6. Interpain A degrades preferentially a-chains of C3 and C4. Purified C3 (A,C) and C4 (B,D) were incubated for 30 min with increasing
concentrations of InpA or 1250 nM of InpAC154A and separated by SDS-PAGE. The gels were stained with silver (A,B), and protein band intensities
corresponding to the a-chains and b-chains of C3 and C4 were analyzed by densitometry (C,D). The graphs show the % of native a- and b-chains
remaining after incubation with InpA. An average of three independent experiments is presented with bars indicating SD. (E) In order to determine
cleavage sites in C3 and C4, these proteins were digested and subjected to N-terminal sequencing. The N-terminal sequences of selected bands are
listed on the right. (F) A schematic representation of C3 and C4 a-chains with indicated sites of cleavage by InpA.
doi:10.1371/journal.ppat.1000316.g006
Interpain A and Complement
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and the deposition of C1q was measured using flow cytometry. We
found that addition of InpA to NHS caused an increase in
deposition of C1q on the surface of Prevotella that mimicked results
obtained using microtiter plates (Figure 8B). Taken together, our
results show that InpA is able to cause deposition of active C1
complex on normally non-activating surfaces such as BSA coated
plastic or bacteria. We did not observe degradation of C1q during
incubation with InpA, neither when InpA was added to NHS nor
when it was incubated with purified C1q (data not shown).
Interpain A acts synergistically with gingipains
Since InpA and gingipains are often present simultaneously at
the sites of infection colonized with P. intermedia and P. gingivalis, we
assessed how they acted on complement when present together.
To this end, InpA and the three gingipains (HRgpA and RgpB are
arginine-specific gingipains while Kgp is lysine-specific) were pre-
incubated with 4% NHS at concentrations chosen to affect the
activity of the lectin pathway by only 10–30%. The deposition of
C3b was assessed and we found that the proteinases acted
synergistically since the deposition of C3b in combinations of InpA
and the gingipains was lower than predicted if the effects of the
proteinases were added separately (Figure 9). For example, InpA
alone decreased the deposition of C3b by 30% at the
concentration used, while Kgp yielded only 25% decrease. When
used together at the same concentrations, InpA and Kgp
decreased C3b deposition by 85% instead of 55% that would be
expected if these proteinases had only additive effects. When all
three gingipains were added together with InpA, the deposition of
C3b was inhibited by 93%.
Discussion
Factors governing P. intermedia infection are poorly studied when
compared to other periodontal pathogens such as P. gingivalis.
However, it is becoming apparent that all successful human
bacterial pathogens must develop strategies to circumvent the
complement system [15]. Microorganisms in gingival sulcus are
immersed in serum-derived tissue exudate—gingival crevicular
fluid, which is similar in composition to human serum. Since
complement components are present in gingival crevicular fluid at
up to 70% of serum concentration [27] and in vivo there is high
level of complement activation in gingival fluid of patients with
periodontitis [28,29], successful evasion of the complement system
is paramount for the survival of P. intermedia in the periodontal
pocket. One such strategy of defense against complement
developed by P. intermedia appears to depend on the production
of InpA, which we now show, is able to degrade complement
Figure 7. Kinetic parameters of InpA-mediated degradation of C3 and C4. (A) Degradation of C3 and C4 incubated with one concentration
of InpA for different time points. (B) Kinetic measurement of degradation of C3b by InpA. Various concentrations of InpA were injected over
immobilized C3b, and the reduction in RU values indicates the extent of proteolytic cleavage of C3b. The inset shows a sensorgram obtained for a
3 mM InpA sample. The initial rates of proteolysis were determined for each InpA concentration from the slope in the sensorgram and plotted as a
function of InpA concentration. (C) Michaelis-Menten plot of degradation of C3 by InpA. InpA was incubated with increasing concentrations of C3,
and the amount of remaining a-chains (substrate) was determined using densitometry after separation on SDS-PAGE. (D) A similar analysis as in (C)
but performed for C4.
doi:10.1371/journal.ppat.1000316.g007
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factor C3, which is the central molecule of the whole complement
system. Importantly, the majority of P. intermedia strains isolated
from aggressive and chronic periodontitis carry and express the
inpA gene.
The proteolytic activities of oral bacteria are thought to play
important roles in the etiology of periodontitis and dental
abscesses. These proteinases may contribute to tissue destruction,
increase availability of nutrients and impair host defense by
degrading immunoglobulins and components of the complement
system. Proteinases of P. intermedia display trypsin-like and
dipeptidylpeptidase activities [30] and also have the properties of
cysteine proteinases [31–33]. They have also been reported to be
capable of degrading immunoglobulins, particularly IgG [34,35],
fibronectin [36] and host proteinase inhibitors [37]. The
degradation of immunoglobulins was mediated mainly by cysteine
proteinase(s) [35]. Now we can add C3 to this list.
Importantly, inhibition of C3 function occurred even when
InpA was incubated with whole NHS showing that C3 will be
specifically degraded even in the presence of all other plasma
proteins (Figures 3–5). This is not the case for C4, which was
degraded efficiently when purified proteins were used but its
function was only weakly affected in the presence of whole serum.
According to kinetic parameters determined with purified
proteins, C4 should be a far better target for InpA than C3 in
serum. Despite that C4 in serum seems to be resistant to
proteolytic inactivation by InpA. To explain this discrepancy, we
speculate that C4 may interact with other protein(s) in serum,
which hinders InpA access to a cleavage site. Alternatively, the a-
chain of C4 may also be susceptible to proteolysis in serum but the
cleaved protein is still a functional source of C4b. The latter
explanation is supported by the observation that in contrast to C3,
proteolysis of C4 is more limited (Figure 6). Such phenomenon has
previously been observed for a2-macroglobulin, which remained
functionally active after cleavage with gingipains [38]. Important-
ly, it is clear that InpA will affect C3 in a way that it can no longer
propagate the complement cascades; which should be of direct
benefit to InpA producing P. intermedia.
Interestingly, InpA showed a preference for the a-chain of C3
and C4, similar to what we have previously observed for
gingipains. At low concentrations, gingipains were able to activate
complement factors C3, C4 and C5 as they preferentially target
the a-chains of these proteins to cause the release of anaphyla-
toxins C3a and C5a as well as the activated forms C3b, C4b and
C5b. Similarly, N-terminal sequencing of C3 and C4 fragments
generated by InpA revealed that InpA will also release C3a and
C4a. At higher concentrations, gingipains simply degrade these
three complement factors, particularly C3, into smaller fragments
so that they can no longer propagate the complement cascade
[19,39]. Yet again, we observe a similar phenomenon for InpA in
case of C3. Also similar to gingipains, InpA was able to cause the
deposition of C1 from serum onto inert surfaces without the need
Figure 8. Deposition of C1q on plates and bacteria. (A) Microtiter
plates were blocked with BSA and incubated with 4% NHS containing
various concentrations of InpA and InpAC154A for 45 min. Deposited
C1q was detected with a specific antibody, and the absorbance
obtained in the absence of InpA was set as 1. (B) P. nigrescens ATCC
25261 was incubated with 5% NHS and different concentrations of InpA
and InpAC154A. Deposition of C1q was quantified using flow cytometry
with specific FITC-labeled antibodies, and the absorbance obtained in
the absence of InpA was set as 1. An average of three independent
experiments is presented with bars indicating SD.
doi:10.1371/journal.ppat.1000316.g008
Figure 9. Interpain A and gingipains act synergistically. Mannan
was immobilized on microtiter plates and allowed to activate 4% NHS
containing 350 nM InpA and three gingipains, Kgp (44 nM), RgpB
(55 nM), HRgpA (33 nM), alone or mixed together. After 20 min of
incubation, the plates were washed, and deposited C3b was detected
with specific antibodies. An average of three independent experiments
is presented with bars indicating SD. Statistical significance of observed
differences was estimated using Student’s t-test; *** p,0.001.
doi:10.1371/journal.ppat.1000316.g009
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for a specific C1 activator; which may lead to local inflammation.
However, whereas this effect could be recreated in vitro using
purified C1 for gingipains [5], InpA required serum to be present
for this to occur (data not shown). Thus, it appears that InpA may
require a third protein to induce C1 deposition from serum.
Consequently, an intricate strategy emerges: periodontal bacteria
at low concentrations appear to cause non-specific activation of C1
and to generate C5a and C3a fragments—chemotactic factors for
neutrophils. This may lead to a low grade inflammation that
provides access to nutrients for bacterial growth and colonization.
At higher concentrations of bacteria and proteinases, the
complement system becomes incapacitated by multiple cleavages
of critical proteins within the cascade.
P. intermedia can be highly resistant to complement and survive
at very high serum concentrations but there are significant
differences between various strains with regard to sensitivity to
killing by complement [13]. In this study, we have shown that
there is a correlation between the presence of InpA and serum
resistance of P. intermedia. Using E. coli as a sensitive model to detect
bactericidal activity of human serum, we have found that they
were able to survive when supplemented with low micromolar
concentrations of InpA in the presence of 2% NHS. In contrast,
cells exposed to NHS alone or to NHS containing the inactive
interpain mutant showed total loss of viability at this serum
concentration. This clearly shows that purified InpA is very
efficient at destroying bactericidal activity of NHS. Further, the
cysteine proteinase inhibitor E64 diminished serum resistance of P.
intermedia strains.
It is plausible that P. intermedia, in similarity to other bacterial
pathogens, has several strategies for evasion of killing by
complement. P. gingivalis employs not only proteinases for defense
from complement [5] but it also produces a surface anionic
polysaccharide, the presence of which strongly correlates with
exceptional serum resistance of these bacteria [40]. This bacterium
also attenuates the effects of complement by capturing human
complement inhibitor C4b-binding protein [16]. In this study, we
have found that P. intermedia was able to retain some of its ability to
resist killing even when incubated with serum containing the
broad-spectrum inhibitor E64. However, InpA is a secreted
protein and we do not expect large amounts of it being present in
our bactericidal assay that has been performed within 1.5 h of
culturing. In vivo, the bacteria will have the opportunity to secrete
much more interpain into its pericellular environment. Our
current methodology does not allow for truly quantitative analysis
of the InpA content in gingival crevicular fluid. However, we can
estimate from our Western blotting analysis that 20 mL of
crevicular fluid contained at least 0.1 mg of InpA. Taking into
account at least 20-fold dilution of crevicular fluid upon collection,
the concentration of InpA in the two positive samples analyzed
must be greater than 100 mg/mL. This corresponds to approx-
imately 4 mM of fully processed InpA, implying that the
concentration of InpA is high enough for inhibition of the
complement system as described to occur in vivo.
Our experiments also showed that InpA will aid survival of
bystander bacterial species, thus, creating a favorable condition for
the establishment of a common ecosystem that would be a
beneficial habitat for all participating species. P. intermedia, together
with Streptococcus gordonii may be considered to be the early
colonizers of tooth surfaces, thereby promoting secondary
colonization of pathogenic organisms such as P. gingivalis by
providing attachment sites, growth substrates and reduced oxygen
concentration locally [41,42]. P. intermedia belongs to the ‘‘orange
complex’’, which encompasses bacterial species bridging between
healthy state and advanced periodontitis. Thus, degradation of C3
by InpA in synergy with gingipains of P. gingivalis will complement
the host immune evasion strategy of subgingival microbiota.
Importantly, Prevotella species readily acquire resistance towards
antibiotics [43] and deeper knowledge of how infection and serum
resistance occur will be crucial for the development of alternative
treatments to periodontal disease.
Materials and Methods
Proteins
Purified complement proteins were purchased from Comple-
ment Technology.
InpA as well as its inactive mutant InpAC154A (the catalytic
cysteine was replaced by alanine) were expressed as His-tagged
recombinant proteins in Escherichia coli and purified by affinity
chromatography on Fast Flow Ni-NTA Sepharose (Qiagen)
followed by anion exchange chromatography (MonoQ, GE
Healthcare) as described previously [25]. The amount of active
enzyme in wild-type InpA preparation was determined by active
site titration using inhibitor E64 (Sigma). Briefly, recombinant
protein was activated at 37uC for 15 min in 0.1 M Tris-HCl,
5 mM EDTA, pH 7.5 freshly supplemented with 2 mM DTT and
then preincubated with increasing concentrations of E64 for
37 min at room temperature. Residual enzyme activity was
determined by measurement of fluorescence (lex = 380 nm and
lem = 460 nm) of AMC released from Boc-Val-Leu-Lys-AMC
(PeptaNova) added to the reaction mixture at 250 mM final
concentration and using the microplate spectrofluorimeter Spec-
traMax Gemini EM (Molecular Devices). The concentration of
active InpA was calculated from the amount of inhibitor needed
for total inactivation of the proteinase. The final preparations of
wild type InpA and InpAC154A were assayed for possible
contamination with lipopolysaccharide using Limulus test (Hycult
Biotechnology) and found to contain 7 and 1 ng/mL lipopolysac-
charide, respectively. Arginine-specific (HRgpA and RgpB) and
lysine-specific (Kgp) gingipains were purified from the P. gingivalis
HG66 strain culture fluid as described previously [5]. Before using
in any assay, InpA and InpAC154A were preactivated for 15 min
by incubation in a buffer specific for the particular assay
supplemented with 2 mM DTT.
Measurement of InpA activity using fluorogenic
substrate
InpA was activated by 15 min incubation in 0.1 M Tris?HCl,
pH 7.6, 5 mM EDTA, 2 mM DTT at 37uC. InpA was mixed
with increasing concentrations of NHS and incubated for 30 min
at 37uC. Control samples without serum and with E64 were
prepared simultaneously. After incubation, the substrate Boc-Val-
Leu-Lys-AMC was added to all samples, rendering final volume
200 mL and final concentrations of 16.8 nM InpA, 0–30% NHS,
100 mM E64 and 5% DMSO. Substrate hydrolysis was monitored
as AMC release. Activity was determined as the initial velocity of
the reaction and expressed in relative fluorescence units (RFU)/s.
Results from triplicates were plotted using GraphPad Prism
software and calculated as relative activity compared to an
uninhibited control.
Bacterial strains and their culture
For detection of P. intermedia in clinical samples, subgingival
plaque samples were obtained from patients with severe
periodontitis (aggressive periodontitis (n = 24), chronic periodon-
titis (n = 58)). Two paper points were inserted in each pocket for
20 s and DNA was subsequently extracted using the Genomic
Mini system (A&A Biotechnology) according to the manufacturer’s
Interpain A and Complement
PLoS Pathogens | www.plospathogens.org 10 February 2009 | Volume 5 | Issue 2 | e1000316
recommendations. PCR was carried out using primers: Pi-1: TTT
GTT GGG GAG TAA AGC GGG and Pi-2: TCA ACA TCT
CTG TAT CCT GCG T [44]. Presence of the inpA gene was
determined using PCR with the following primers that were
designed based on Oral Pathogen Sequence Database (gene
pPI0032; http://www.oralgen.lanl.gov): pPI-1: GAA GGA CAA
CTA CAG CGG AAA; pPI-2: TCC TTT CGT TAG TTC GCT
GA. Some of the samples were cultivated on Schaedler agar and
Schaedler agar supplemented with 7.5 mg/L vancomycin. Colo-
nies typical for P. intermedia were then subcultivated yielding strains
57, 59, 120, 106, BGH10, BGH30, H13 and their identification
was confirmed by PCR exactly as described previously [45]. P.
intermedia OMZ 248 [46], was kindly provided by Dr. Frandsen
(Department of Oral Biology, Royal Dental College, Faculty of
Health Sciences, University of Aarhus, Denmark). For the
experiments conducted in this study, all P. intermedia strains were
grown on blood-enriched tryptic soy broth (TSB) agar plates at
37uC in an anaerobic chamber (Concept 400, Biotrace) with an
atmosphere of 90% N2, 5% CO2 and 5% H2. Escherichia coli
laboratory strain DH5a (Invitrogen) and Escherichia coli clinical
strain were grown on standard Luria-Bertani (LB) agar plates or in
LB broth. Prevotella nigrescens (ATCC 25261) was grown on BBL
Columbia II agar containing 8.5% horse blood, 0.04% L-cysteine
HCl, 5 mg/mL hemin and 2 mg/mL vitamin K1. Bacterial
strains used in this study are listed in Table 2.
Sampling of crevicular fluid and analysis
Crevicular washes were obtained using a previously described
method from 4 patients with chronic periodontitis. For analysis of
P. intermedia presence, DNA was extracted from 5 mL of crevicular
fluid using the High Pure PCR Template Preparation Kit (Roche)
according to the manufacturer’s recommendations. Real-time
PCR was carried out using a RotorGene 2000 (Corbett Research).
Primers specific for 16S rDNA from P. intermedia were designed as
described by [44]. PCR amplification was carried out as described
earlier [47]. Determination of InpA in gingival crevicular fluid
samples was performed by Western blotting analysis using rabbit
polyclonal Ab against 40 kDa (without C-terminal profragment)
form of InpA raised in rabbits by standard immunization with
purified recombinant InpAC154A.
Bactericidal assay
Strain E. coli DH5a was cultured in LB broth until exponential
growth phase. Cells were harvested, washed once in GVB++
(5 mM veronal buffer pH 7.3, 140 mM NaCl, 0.1% gelatin,
1 mM MgCl2 and 0.15 mM CaCl2) and adjusted to an optical
density at 600 nm of 0.5. NHS was prepared from blood taken
from six healthy volunteers and pooled. NHS was diluted in
GVB++ to a concentration of 2% and incubated with various
concentrations of preactivated InpA or InpAC154A for 15 min at
RT. Thereafter, 104 bacteria cells were added and incubated with
serum supplemented with InpA for 20 min at 37uC in a total
volume of 60 ml. After incubation, aliquots were removed, diluted
serially and spread onto LB agar plates. Heat inactivated serum
(56uC, 30 min) was used as a negative control. Plates were
incubated for 12 h in 37uC after which colonies were counted and
percentages of the surviving bacteria were calculated.
P. intermedia from four-day old agar plate culture were harvested
and washed once in GVB++ and adjusted to an optical density at
600 nm of 0.6. Thereafter, 26104 bacteria were mixed with 20%
NHS diluted in GVB++ and incubated anaerobically for 1.5 h at
37uC in total volume of 110 ml. The aliquots were removed,
diluted serially and spread onto TSB plates. Plates were incubated
for 4 days at 37uC in an anaerobic chamber after which colonies
were counted and percentages of the surviving bacteria were
calculated. E. coli were treated in a similar manner except for that
40% NHS was used. All incubations were performed aerobically
and the bacteria were spread on LB agar plates for counting
colonies after overnight incubation.
Western blot analysis of interpain A expression
P. intermedia strains OMZ 248, 59, 57, 120, 106, BGH 10, BGH
30, H13 and ATCC 25611 were cultured in the Schaedler liquid
medium at 37uC in an anaerobic chamber for 5 days. Aliquots of
cell culture media adjusted to an optical density at 600 nm of 2.0
were separated under reducing conditions by SDS-PAGE
electrophoresis using 12% gel. The proteins were transferred onto
PVDF membrane using semi-dry blotting system. After blocking
with 50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, 0.1%
Tween 20 and 3% fish gelatin, pH 8.0, InpA was visualized using
an anti-InpA polyclonal antibody (1:500 dilution) followed by goat
anti-rabbit Abs conjugated to HRP and developed using enhanced
chemiluminescence (ECL). The signals were collected using CCD
camera (LAS3000, Fujifilm).
Hemolytic assay
To assess activity of the classical pathway, sheep erythrocytes
were washed three times with DGVB++ buffer (2.5 mM veronal
buffer pH 7.3, 70 mM NaCl, 140 mM glucose, 0.1% gelatin,
1 mM MgCl2 and 0.15 mM CaCl2). The cells were incubated
with a complement-fixing antibody (amboceptor; Boehringverke;
diluted 1:3000 in DGVB++ buffer) at a concentration of 109 cells/
mL for 20 min at 37uC. After two washes with DGVB++, 56108
cells/mL were incubated for 1 h at 37uC with 1.25% NHS diluted
in DGVB++ buffer (total volume 200 ml). Before incubation with
erythrocytes, NHS was pre-incubated with various concentrations
of preactivated InpA or InpAC154A for 15 min at RT. The buffer
used for activation of InpA did not interfere with the hemolytic
assay or erythrocytes (data not shown). The samples were
centrifuged and the amount of lysed erythrocytes was determined
by spectrophotometric measurement of the amount of released
hemoglobin (405 nm).
To assess activity of the alternative pathway, rabbit erythrocytes
were washed three times with Mg++EGTA buffer (2.5 mM veronal
buffer, containing 70 mM NaCl, 140 mM glucose, 0.1% gelatin,
Table 2. Description of bacterial strains used in this study.
Bacterial strain Characteristics
Escherichia coli DH5a Common laboratory strain
Escherichia coli Clinical strain isolated from a patient with
urinary tract infection.
P. nigrescens (ATCC 25261) Laryngotomy wound
P. intermedia (ATCC 25611) Empyema
P. intermedia 59 Severe chronic periodontitis
P. intermedia 57 Severe chronic periodontitis
P. intermedia OMZ 248 Severe chronic periodontitis
P. intermedia 120 Aggressive periodontitis
P. intermedia 106 Severe chronic periodontitis
P. intermedia BGH 10 Severe chronic periodontitis
P. intermedia BGH 30 Severe chronic periodontitis
P. intermedia H13 Aggressive periodontitis
doi:10.1371/journal.ppat.1000316.t002
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7 mM MgCl2, 10 mM EGTA, pH 7.3). Erythrocytes at a
concentration of 56108 cells/mL were then incubated for 1.5 h
at 37uC with 10% NHS diluted in Mg++ EGTA buffer (total
volume 200 ml). NHS used was pre-treated with various
concentrations of preactivated InpA or InpAC154A for 15 min
at RT. The samples were centrifuged and the amount of lysed
erythrocytes was determined spectrophotometrically.
Complement activation assays
Microtiter plates (Maxisorp; Nunc) were incubated overnight at
4uC with 50 ml of a solution containing 2 mg/mL human
aggregated IgG (Immuno), 100 mg/mL mannan (Sigma, M-
7504) or 20 mg/mL zymosan (Sigma, Z-4250) in 75 mM sodium
carbonate (pH 9.6). Between each step of the procedure, the plates
were washed four times with 50 mM Tris-HCl, 150 mM NaCl,
and 0.1% Tween 20 (pH 7.5). The wells were blocked with 1%
BSA (Sigma) in PBS for 2 h at RT. NHS was diluted in GVB++
buffer and used at a concentration of 2% for C3b, C4b, C1q
(classical pathway), 4% for C3b, C4b, MBL (lectin pathway), 6%
for C3 (alternative pathway) and 10% for C9 (all three pathways).
These concentrations were chosen on the basis of initial titrations.
NHS was mixed with various concentrations of preactivated InpA
or InpAC154A and incubated in the wells of microtiter plates for
45 min at 37uC for C9 and MBL and 20 min at 37uC for C3b and
C4b in case of the alternative and the lectin pathways. For the
classical pathway, NHS was incubated with preactivated InpA or
InpAC154A for 15 min at RT in eppendorf tubes and the enzyme
was inhibited by addition of 20 mM E-64 (Calbiochem) to avoid
degradation of IgM deposited on plates. Immediately after
addition of inhibitor, NHS was incubated in microtiter plates for
45 min at 37uC for C9 and C1q and 20 min at 37uC for C3b and
C4b. The inhibitor itself did not affect activation of complement at
the concentration used (data not shown). Complement activation
was assessed by detecting deposited complement factors using
rabbit anti-C1q, anti-C4b, anti-C3d polyclonal antibodies (pAbs,
DakoCytomation) goat anti-C9 pAb (Complement Technology)
and goat anti-MBL (R&D) diluted in the blocking buffer. Bound
antibodies were detected with HRP-labeled anti-rabbit or anti-
goat secondary pAb (DakoCytomation). Bound HRP-labelled pAb
were detected with 1,2-phenylenediamine dihydrochloride (OPD)-
tablets (DakoCytomation) and the absorbance was measured at
490 nm.
To assess deposition of purified C1q on microtiter plates
without any complement activator, plates were blocked with 1%
BSA in PBS for 2 h at RT. NHS was diluted in GVB++ buffer to
4% and mixed with various concentration of interpain A. Plates
were incubated for 45 min at 37uC with shaking and the deposited
C1q was detected with specific antibodies.
Deposition of C1q on bacteria
P. nigrescens ATCC 25261 from two-day old agar plate cultures
were harvested, washed twice in GVB++ buffer and adjusted to an
optical density at 600 nm of 1.0. NHS was diluted in GVB++ to a
concentration of 5%, mixed with 66105 cells and incubated with
various concentrations of preactivated InpA or InpAC154A for
30 min at 37uC. Thereafter, the cells were washed twice in the
binding buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl,
1 mM MgCl2, 2 mM CaCl2, pH 7.2). C1q deposition was
assessed by incubation of the cells with rabbit anti-human C1q
FITC-conjugated polyclonal antibodies (DakoCytomation, diluted
in the binding buffer 1:100) for 1 h. The cells were washed twice in
the binding buffer and finally resuspended in flow cytometry buffer
(50 mM HEPES, 100 mM NaCl, 30 mM NaN3, 1% BSA;
pH 7.4). Flow cytometry analysis was performed using FACS
Calibur (Beckton Dickinson).
Degradation assay
C4 and C3 (0.8 mM each) were incubated with InpA at
concentrations ranging from 50 nM to 1250 nM. Incubations were
carried out in 0.2 M Tris-HCl, pH 7.4, containing 0.1 M NaCl,
5 mM CaCl2 and 2 mM DTT for 30 min at 37uC. For the time
course experiment, C4 and C3 (0.8 mM each) were incubated with
640 nM InpA for 5, 10, 20, 30, 45, 60 and 75 min. The proteins were
separated by SDS-PAGE electrophoresis using standard Laemmli
procedure and 12% gels. Prior to electrophoresis the samples were
boiled for 5 min at 95uC in a sample loading buffer containing
25 mM DTT and 4% SDS. After separation, the gels were stained
with silver salts to visualize the separated proteins and quantified by
densitometry using ImageGauge (FujiFilm, Tokyo, Japan).
N-terminal sequencing
To determine sites of cleavage by InpA, 10 mg of C3 and C4
were incubated with 500 nM preactivated InpA for 2 h at 37uC
and the proteins were separated by 12% SDS-PAGE under
reducing condition. The proteins were then transferred to PVDF
membranes (Pall) and stained using Coomassie Blue. Bands of
interest were excised and analyzed by automated Edman
degradation in an Applied Biosystems PROCISE 494 HT
sequencer with on-line phenylthiohydantion HPLC analysis using
a 140 C Microgradient System from Applied Biosystems, operated
according to the manufacturer’s recommendations.
Kinetic measurements using surface plasmon resonance
(Biacore)
The analysis was performed according to a previously published
protocol [48]. Human C3b was diluted in 10 mM Na-acetate
pH 4.0 to a concentration of 30 mg/mL and immobilized on chip
CM5 to a level of 3000 RU using amino coupling kit (Biacore) and
Biacore 2000. Interpain A was pre-activated by 15 min activation
at 37uC in the running buffer (10 mM HEPES, 150 mM NaCl,
1 mM MgCl2, 0.15 mM CaCl2, 0.005% Tween 20, 0.2 mM
DTT; pH 7.4) with 2 mM DTT and diluted in the running buffer
in a concentration range 0.25–6 mM. Interpain A was then
injected at the flow rate of 5 ml/min at 37uC over the immobilized
C3met and its activity was quantified as decrease in RU on the
sensorgram and analyzed using Biaevaluation software (Biacore).
Determination of kinetic parameters of C3 and C4
degradation by InpA
Several concentrations of C3 (1.2–7.2 mM) and C4 (0.2–
4.8 mM) diluted in DGVB++ were incubated with 110 nM or
40 nM of preactivated InpA, respectively. The incubation time
was 4 h and 20 min for C3 and C4, respectively. In parallel, the
same concentrations of C3 and C4 were incubated without
enzyme. Proteins were separated under reducing conditions by
SDS PAGE using 12% gel, stained with Coomassie and the gels
were scanned followed by densitometry determination of a-chains
of C3 and C4 (ImageGauge). Intensity of a-chain bands in the
presence of InpA was compared to corresponding controls and
expressed as the amount of substrate remaining. Initial velocity of
the reaction at each concentration was calculated as amount of
substrate consumed within one second and fitted by nonlinear
regression into the Michaelis-Menten equation V = (kcat*[E]t*[S])/
([S]+Km) using GraphPad Prism. Values Km and kcat were obtained
as regression curve parameters. Similar values were obtained from
two independent experiments.
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Ethics statement
The ethical board of Lund University has approved collection of
sera from healthy human volunteers. The ethical committee of
Jena University approved collection of periodontal plaques and
crevicular fluid. Informed consent was obtained from patients and
the investigation was performed according to principles of the
Declaration of Helsinki.
Statistical analysis
Student’s t-test was used to calculate the p values in order to
estimate if the observed differences between experimental results
were statistically significant.
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